Claims
- 1. A method of treating glial tumors in a subject comprising:
providing a glutamate antagonist and administering the glutamate antagonist to a subject with a glial tumor under conditions effective to treat the glial tumor.
- 2. The method according to claim 1, wherein said glial tumor is located in the brain of the subject.
- 3. The method according to claim 1, wherein said glial tumor is located in the spinal cord of the subject.
- 4. The method according to claim 1, wherein said glial tumor is malignant.
- 5. The method according to claim 1, wherein said glial tumor is benign.
- 6. The method according to claim 1, wherein said glutamate antagonist blocks glutamate function at an ionotropic glutamate receptor.
- 7. The method according to claim 6, wherein said ionotropic glutamate receptor is a NMDA receptor.
- 8. The method according to claim 6, wherein said ionotropic glutamate receptor is an AMPA receptor.
- 9. The method according to claim 6, wherein said ionotropic glutamate receptor is a kainate receptor.
- 10. The method according to claim 6, wherein said glutamate antagonist binds to the ionotropic glutamate receptor.
- 11. The method according to claim 6, wherein said glutamate antagonist interacts with an ionotropic glutamate receptor ion channel.
- 12. The method according to claim 6, wherein said glutamate antagonist interacts with glutamate.
- 13. The method according to claim 6, wherein said glutamate antagonist is an antibody which binds to ionotropic glutamate receptors.
- 14. The method according to claim 1, wherein the subject is a mammal.
- 15. The method according to claim 14, wherein the mammal is a human subject.
- 16. The method according to claim 1, wherein said administering is carried out orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by implantation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, transdermally, or by application to mucous membranes.
- 17. The method according to claim 1, wherein the glutamate antagonist is present in a pharmaceutical composition comprising the glutamate antagonist and a pharmaceutically-acceptable carrier.
- 18. A method of treating glial tumors in a subject comprising:
providing a NMDA receptor antagonist and administering the NMDA receptor antagonist to a subject with a glial tumor under conditions effective to treat the glial tumor.
- 19. The method according to claim 18, wherein said glial tumor is located in the brain of the subject.
- 20. The method according to claim 18, wherein said glial tumor is located in the spinal cord of the subject.
- 21. The method according to claim 18, wherein said glial tumor is malignant.
- 22. The method according to claim 18, wherein said glial tumor is benign.
- 23. The method according to claim 18, wherein said NMDA receptor antagonist blocks glutamate function at NMDA receptor complexes.
- 24. The method according to claim 23, wherein said NMDA receptor antagonist binds to a NMDA receptor.
- 25. The method according to claim 23, wherein said NMDA receptor antagonist interacts with NMDA ion channels.
- 26. The method according to claim 23, wherein said NMDA receptor antagonist is an antibody to NMDA receptors.
- 27. The method according to claim 23, wherein said NMDA receptor antagonist is MK801.
- 28. The method according to claim 23, wherein said NMDA receptor antagonist is memantine.
- 29. The method according to claim 18, wherein the subject is a mammal.
- 30. The method according to claim 29, wherein the mammal is a human subject.
- 31. The method according to claim 29, wherein said administering is carried out orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by implantation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, transdermally, or by application to mucous membranes.
- 32. The method according to claim 18, wherein said NMDA receptor antagonist is present in a pharmaceutical composition comprising the NMDA receptor antagonist and a pharmaceutically-acceptable carrier.
Parent Case Info
[0001] The present application claims benefit of U.S. Provisional Patent Application Serial No. 60/313,030, filed Aug. 20, 2001.
Government Interests
[0002] The subject matter of this application was made with support from the United States Government under grant numbers NS30007 and NS38073. The United States Government may have certain rights.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60313030 |
Aug 2001 |
US |